Note 1 - Summary of Significant Accounting Policies (Detail) - Percentage of Total Revenue From Licenses Over 10% of Revenue	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Genentech [Member] | Avastin [Member]
Licensee	30.00%	27.00%
Genentech [Member] | Herceptin [Member]
Licensee	33.00%	30.00%
Genentech [Member] | Lucentis [Member]
Licensee	14.00%	11.00%
Elan [Member] | Tysabri [Member]
Licensee	15.00%	12.00%